| خلاصه مقاله | Aim: Systemic sclerosis (SSC) is a systemic condition with various manifestations in different organs. Among these organs, the lungs are affected very frequently, and the involvement is progressive and significant. Various medications have been suggested and tested in patients with SSC and lung involvement, but their efficacy and safety profile differ and enforce a final decision-making difficult. Cyclophosphamide is an example in this regard. This study sought to examine the therapeutic effect of this drug in patients with scleroderma and lung disease.
Methods & Materials: A total of 20 patients with SSC and parenchymal lung disease received intravenous cyclophosphamide (500 mg/m2) along with gradually tapering prednisolone (20-7.5 mg/day) and azathioprine (2mg/kg) after discontinuation of the former for six consecutive months. The Transition Dyspnea Index (TDI), Forced Vital Capacity (FVC), Total Lung Capacity (TLC), Diffusion Lung Carbon monoxide (DLCO), 17 revised Rodnan Score, and high resolution computed tomography (HRCT) scan results were examined 3 and 6 months after starting the treatment.
Results: After 6 months of treatment, there was not significant increase in FVC (4.56%, p=0.14), TLC (0.83%, p=0.23) and 17 revised Rodnan Score (0.04%, p=0.67). The trend in TDI was neither specific nor significant (p=0.79). The HRCT Scan, had not significantly changes 6 months after treatment compared to the baseline findings (p=0.402)
Conclusion: In the current study, the changes at FVC, FEV1, TLC, DLCO, dyspnea, high resolution CT scan, and skin thickening before and after the treatment were not significant. |